Kelly Makarounas-Kirchmann


If you made any changes in Pure these will be visible here soon.

Personal profile


Kelly Makarounas-Kirchmann is an economist with more than 20 years experience in the pharmaceutical industry. Her breadth of knowledge covers all facets of the reimbursement process and her skill base lies in developing, conducting, communicating and implementing reimbursement and pricing strategies. This also incorporates the many facets of market access and commercialisation.

The role of Health Economics Manager with the Australian Pharmaceutical Manufacturers Association (APMA; now Medicines Australia) was her introduction into the pharmaceutical industry. In this role she represented industry at various government levels and was their representative on the Economics Working Party of the Pharmaceutical Benefits Advisory Committee (PBAC) and other industry working parties, as well as, at the time, being intricately involved with policy initiatives.

Since 2002 her commitment to the area of health economics was cemented with a lecturing position at Monash, teaching students undertaking their Masters of Public Health.

The establishment of KMC Health Care in 2002 was based on the principal of ensuring delivery of service to clients utilising the expertise of highly skilled consultants. Her team's breadth of skills and knowledge has come from many years of working in the healthcare industry and the continuous updating of our knowledge.

KMC Health Care specialises in health sector issues including early product development, pharmacy, product commercialisation strategy, policy, HTA and reimbursement of pharmaceuticals in Australia, New Zealand, Asia and Europe.

Research Output 1993 2012

Pharmaceutical benefit advisory committee acceptability threshold results 2005-2011

Makarounas-Kirchmann, K., Ademi, Z. & Kirchmann, M., 2012, In : Value in Health. 15, 7, p. 622 - 622 1 p.

Research output: Contribution to journalLetterOther

7 Citations (Scopus)

Letter to the Editor

Makrounas-Kirchmann, K., Glover-Koudounas, S. & Ferrari, P., Feb 2010, In : Clinical Therapeutics. 32, 2, p. 397 1 p.

Research output: Contribution to journalLetterOtherpeer-review

31 Citations (Scopus)

Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers

Makarounas-Kirchmann, K., Glover-Koudounas, S. & Ferrari, P., 2009, In : Clinical Therapeutics. 31, 8, p. 1652 - 1663 12 p.

Research output: Contribution to journalArticleResearchpeer-review